Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 323


Characteristics of graft-versus-host disease occurring after alemtuzumab-containing allogeneic stem cell transplants: incidence, organ involvement, risk factors and survival.

Finazzi MC, Boschini C, Craddock C, Rambaldi A, Ward J, Malladi RK.

Br J Haematol. 2019 Nov 12. doi: 10.1111/bjh.16200. [Epub ahead of print]


Trial re-investment to build better research for better impact.

Fox TA, Horne GA, Craddock C, Cook G, O'Brien S, Fox S, Hockaday A, Silk G, Hillmen P.

Lancet. 2019 Aug 24;394(10199):635-636. doi: 10.1016/S0140-6736(19)31363-7. No abstract available.


Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Halaburda K, Labopin M, Mailhol A, Socié G, Craddock C, Aljurf M, Beelen D, Cornelissen JJ, Bourhis JH, Labussière-Wallet H, Blaise D, Gedde-Dahl T, Gilleece M, Yakoub-Agha I, Mufti G, Esteve J, Mohty M, Nagler A.

Haematologica. 2019 Aug 22. pii: haematol.2019.222810. doi: 10.3324/haematol.2019.222810. [Epub ahead of print]


Allogeneic haemopoietic transplantation for acute myeloid leukaemia in second complete remission: a registry report by the Acute Leukaemia Working Party of the EBMT.

Gilleece MH, Labopin M, Savani BN, Yakoub-Agha I, Socié G, Gedde-Dahl T, Blaise D, Byrne JL, Craddock C, Cornelissen JJ, Arcese W, Forcade E, Crawley C, Polge E, Mohty M, Nagler A.

Leukemia. 2019 Jul 30. doi: 10.1038/s41375-019-0527-4. [Epub ahead of print]


Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.

Kinsella FAM, Inman CF, Gudger A, Chan YT, Murray DJ, Zuo J, McIlroy G, Nagra S, Nunnick J, Holder K, Wall K, Griffiths M, Craddock C, Nikolousis E, Moss P, Malladi R.

Leuk Res. 2019 Aug;83:106173. doi: 10.1016/j.leukres.2019.106173. Epub 2019 Jun 18.


The prognostic impact of the cytomegalovirus serostatus in patients with chronic hematological malignancies after allogeneic hematopoietic stem cell transplantation: a report from the Infectious Diseases Working Party of EBMT.

Schmidt-Hieber M, Tridello G, Ljungman P, Mikulska M, Knelange N, Blaise D, Socié G, Volin L, Blijlevens N, Fegueux N, Yakoub-Agha I, Forcade E, Maertens J, Chevallier P, Passweg J, Cornelissen J, Russell N, Craddock C, Bourhis JH, Marchand T, Reményi P, Cahn JY, Michallet M, Montoto S, Kröger N, Glaß B, Styczynski J.

Ann Hematol. 2019 Jul;98(7):1755-1763. doi: 10.1007/s00277-019-03669-z. Epub 2019 Apr 16.


Mixed chimerism established by hematopoietic stem cell transplantation is maintained by host and donor T regulatory cells.

Kinsella FAM, Zuo J, Inman CF, Pearce H, Maggs L, Eldershaw SE, Chan YLT, Nunnick J, Nagra S, Griffiths M, Craddock C, Malladi R, Moss P.

Blood Adv. 2019 Mar 12;3(5):734-743. doi: 10.1182/bloodadvances.2018025502.


A Comparison of Inpatient and Outpatient-Based Chemotherapy Regimens for the Treatment of Acute Myeloid Leukaemia In The Elderly.

Daly AB, Cuthbert R, Finnegan D, Arnold C, Craddock C, McMullin MF.

Ulster Med J. 2019 Jan;88(1):25-29. Epub 2019 Jan 22.


Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation.

Gagelmann N, Eikema DJ, Stelljes M, Beelen D, de Wreede L, Mufti G, Knelange NS, Niederwieser D, Friis LS, Ehninger G, Nagler A, Yakoub-Agha I, Meijer E, Ljungman P, Maertens J, Kanz L, Lopez-Corral L, Brecht A, Craddock C, Finke J, Cornelissen JJ, Bernasconi P, Chevallier P, Sierra J, Robin M, Kröger N.

Haematologica. 2019 May;104(5):929-936. doi: 10.3324/haematol.2018.200808. Epub 2019 Jan 17.


Antilymphocyte globulin for matched sibling donor transplantation in patients with myelofibrosis.

Robin M, Chevret S, Koster L, Wolschke C, Yakoub-Agha I, Bourhis JH, Chevallier P, Cornelissen JJ, Reményi P, Maertens J, Poiré X, Craddock C, Socié G, Itälä-Remes M, Schouten HC, Marchand T, Passweg J, Blaise D, Damaj G, Ozkurt ZN, Zuckerman T, Cluzeau T, Labussière-Wallet H, Cammenga J, McLornan D, Chalandon Y, Kröger N.

Haematologica. 2019 Jun;104(6):1230-1236. doi: 10.3324/haematol.2018.201400. Epub 2019 Jan 17.


Combination Lenalidomide and Azacitidine: A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia.

Craddock C, Slade D, De Santo C, Wheat R, Ferguson P, Hodgkinson A, Brock K, Cavenagh J, Ingram W, Dennis M, Malladi R, Siddique S, Mussai F, Yap C.

J Clin Oncol. 2019 Mar 1;37(7):580-588. doi: 10.1200/JCO.18.00889. Epub 2019 Jan 17.


Which patients with acute myeloid leukemia in CR1 can be spared an allogeneic transplant?

Craddock C, Raghavan M.

Curr Opin Hematol. 2019 Mar;26(2):58-64. doi: 10.1097/MOH.0000000000000482.


We do still transplant CML, don't we?

Craddock CF.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):177-184. doi: 10.1182/asheducation-2018.1.177. Review.


Targeting the arginine metabolic brake enhances immunotherapy for leukaemia.

Mussai F, Wheat R, Sarrou E, Booth S, Stavrou V, Fultang L, Perry T, Kearns P, Cheng P, Keeshan K, Craddock C, De Santo C.

Int J Cancer. 2019 Oct 15;145(8):2201-2208. doi: 10.1002/ijc.32028. Epub 2019 Jan 11.


Natural variation in acyl editing is a determinant of seed storage oil composition.

Menard GN, Bryant FM, Kelly AA, Craddock CP, Lavagi I, Hassani-Pak K, Kurup S, Eastmond PJ.

Sci Rep. 2018 Nov 26;8(1):17346. doi: 10.1038/s41598-018-35136-6.


Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.

Brierley CK, Jones FM, Hanlon K, Peniket AJ, Hatton C, Collins GP, Schuh A, Medd P, Clark A, Ward J, Chaganti S, Malladi R, Parker A, Craddock C, Danby R, Rocha V.

Br J Haematol. 2019 Feb;184(4):547-557. doi: 10.1111/bjh.15685. Epub 2018 Nov 22.


Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission.

Lorentino F, Labopin M, Bernardi M, Ciceri F, Socié G, Cornelissen JJ, Esteve J, Ruggeri A, Volin L, Yacoub-Agha I, Craddock C, Passweg J, Blaise D, Gedde-Dahl T, Poiani M, Fegueux N, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Am J Hematol. 2018 Oct;93(10):1236-1244. doi: 10.1002/ajh.25231. Epub 2018 Sep 3.


CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes.

de Lima M, Oran B, Champlin RE, Papadopoulos EB, Giralt SA, Scott BL, William BM, Hetzer J, Laille E, Hubbell B, Skikne BS, Craddock C.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2017-2024. doi: 10.1016/j.bbmt.2018.06.016. Epub 2018 Jun 20.


Current status and future clinical directions in the prevention and treatment of relapse following hematopoietic transplantation for acute myeloid and lymphoblastic leukemia.

Craddock C, Hoelzer D, Komanduri KV.

Bone Marrow Transplant. 2019 Jan;54(1):6-16. doi: 10.1038/s41409-018-0203-8. Epub 2018 May 31.


Unique features and clinical importance of acute alloreactive immune responses.

Inman CF, Eldershaw SA, Croudace JE, Davies NJ, Sharma-Oates A, Rai T, Pearce H, Sirovica M, Chan YLT, Verma K, Zuo J, Nagra S, Kinsella F, Nunnick J, Amel-Kashipaz R, Craddock C, Malladi R, Moss P.

JCI Insight. 2018 May 17;3(10). pii: 97219. doi: 10.1172/jci.insight.97219. eCollection 2018 May 17.


Patterns of thought: Population variation in the associations between large-scale network organisation and self-reported experiences at rest.

Wang HT, Bzdok D, Margulies D, Craddock C, Milham M, Jefferies E, Smallwood J.

Neuroimage. 2018 Aug 1;176:518-527. doi: 10.1016/j.neuroimage.2018.04.064. Epub 2018 May 4.


Conditioning intensity in HCT for AML: the jury is still out.

Craddock C.

Lancet Haematol. 2018 Apr;5(4):e132-e133. doi: 10.1016/S2352-3026(18)30035-8. Epub 2018 Mar 14. No abstract available.


Incidence, Risk Factors, and Long-term Outcome of Acute Leukemia Patients With Early Candidemia After Allogeneic Stem Cell Transplantation: A Study by the Acute Leukemia and Infectious Diseases Working Parties of European Society for Blood and Marrow Transplantation.

Cesaro S, Tridello G, Blijlevens N, Ljungman P, Craddock C, Michallet M, Martin A, Snowden JA, Mohty M, Maertens J, Passweg J, Petersen E, Nihtinen A, Isaksson C, Milpied N, Rohlich PS, Deconinck E, Crawley C, Ledoux MP, Hoek J, Nagler A, Styczynski J.

Clin Infect Dis. 2018 Aug 1;67(4):564-572. doi: 10.1093/cid/ciy150.


Cord Blood Unit Dominance Analysis and Effect of the Winning Unit on Outcomes after Double-Unit Umbilical Cord Blood Transplantation in Adults with Acute Leukemia: A Retrospective Study on Behalf of Eurocord, the Cord Blood Committee of Cellular Therapy, Immunobiology Working Party, and the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Tozatto-Maio K, Giannotti F, Labopin M, Ruggeri A, Volt F, Paviglianiti A, Kenzey C, Hayashi H, Cornelissen J, Michallet M, Karakasis D, Deconinck E, Rohrlich PS, de la Tour RP, Blaise D, Petersen E, D'Aveni M, Sengeloev H, Lamy T, Russell NH, Forcade E, Craddock CF, Nagler A, Gluckman E, Rocha V.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1657-1663. doi: 10.1016/j.bbmt.2018.02.014. Epub 2018 Mar 1.


Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1.

Versluis J, Labopin M, Ruggeri A, Socie G, Wu D, Volin L, Blaise D, Milpied N, Craddock C, Yakoub-Agha I, Maertens J, Ljungman P, Huynh A, Michallet M, Deconinck E, Chevallier P, Passweg J, Ciceri F, Mohty M, Cornelissen JJ, Nagler A.

Blood Adv. 2017 Feb 28;1(7):477-485. doi: 10.1182/bloodadvances.2016002386. eCollection 2017 Feb 28.


Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia.

Quek L, Ferguson P, Metzner M, Ahmed I, Kennedy A, Garnett C, Jeffries S, Walter C, Piechocki K, Timbs A, Danby R, Raghavan M, Peniket A, Griffiths M, Bacon A, Ward J, Wheatley K, Vyas P, Craddock C.

Blood Adv. 2016 Dec 14;1(3):193-204. doi: 10.1182/bloodadvances.2016000760. eCollection 2016 Dec 27.


The number of CD56dim NK cells in the graft has a major impact on risk of disease relapse following allo-HSCT.

Maggs L, Kinsella F, Chan YLT, Eldershaw S, Murray D, Nunnick J, Bird J, Craddock C, Zuo J, Malladi R, Moss P.

Blood Adv. 2017 Aug 21;1(19):1589-1597. doi: 10.1182/bloodadvances.2017008631. eCollection 2017 Aug 22.


Allogeneic stem cell transplantation benefits for patients ≥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Poiré X, Labopin M, Polge E, Passweg J, Craddock C, Blaise D, Cornelissen JJ, Volin L, Russell NH, Socié G, Michallet M, Fegueux N, Chevallier P, Brecht A, Hunault-Berger M, Mohty M, Esteve J, Nagler A.

Haematologica. 2018 Feb;103(2):256-265. doi: 10.3324/haematol.2017.178251. Epub 2017 Dec 14.


Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia.

Craddock C, Versluis J, Labopin M, Socie G, Huynh A, Deconinck E, Volin L, Milpied N, Bourhis JH, Rambaldi A, Chevallier P, Blaise D, Manz M, Vellenga E, Vekemans MC, Maertens J, Passweg J, Vyas P, Schmid C, Löwenberg B, Ossenkoppele G, Mohty M, Cornelissen JJ, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and HOVON-SAKK.

J Intern Med. 2018 Apr;283(4):371-379. doi: 10.1111/joim.12720. Epub 2018 Jan 5.


Allogeneic Stem Cell Transplantation for Myelodysplastic Syndrome Patients with a 5q Deletion.

Garderet L, Ziagkos D, van Biezen A, Iacobelli S, Finke J, Maertens J, Volin L, Ljungman P, Chevallier P, Passweg J, Schaap N, Beelen D, Nagler A, Blaise D, Poiré X, Yakoub-Agha I, Lenhoff S, Craddock C, Schots R, Rambaldi A, Sanz J, Jindra P, Mufti GJ, Robin M, Kröger N.

Biol Blood Marrow Transplant. 2018 Mar;24(3):507-513. doi: 10.1016/j.bbmt.2017.11.017. Epub 2017 Nov 28.


NK cells produce high levels of IL-10 early after allogeneic stem cell transplantation and suppress development of acute GVHD.

Chan YLT, Zuo J, Inman C, Croft W, Begum J, Croudace J, Kinsella F, Maggs L, Nagra S, Nunnick J, Abbotts B, Craddock C, Malladi R, Moss P.

Eur J Immunol. 2018 Feb;48(2):316-329. doi: 10.1002/eji.201747134. Epub 2017 Oct 27.


Outcome of Azacitidine Therapy in Acute Myeloid Leukemia Is not Improved by Concurrent Vorinostat Therapy but Is Predicted by a Diagnostic Molecular Signature.

Craddock CF, Houlton AE, Quek LS, Ferguson P, Gbandi E, Roberts C, Metzner M, Garcia-Martin N, Kennedy A, Hamblin A, Raghavan M, Nagra S, Dudley L, Wheatley K, McMullin MF, Pillai SP, Kelly RJ, Siddique S, Dennis M, Cavenagh JD, Vyas P.

Clin Cancer Res. 2017 Nov 1;23(21):6430-6440. doi: 10.1158/1078-0432.CCR-17-1423. Epub 2017 Aug 1.


Chilli-too hot to handle?

Craddock C, Cathcart P, Stebbing J.

Lancet Oncol. 2017 Aug;18(8):1005. doi: 10.1016/S1470-2045(17)30522-3. Epub 2017 Jul 26. No abstract available.


Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making.

Yap C, Billingham LJ, Cheung YK, Craddock C, O'Quigley J.

Clin Cancer Res. 2017 Dec 15;23(24):7440-7447. doi: 10.1158/1078-0432.CCR-17-0582. Epub 2017 Jul 21.


Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Jul;52(7):1081. doi: 10.1038/bmt.2017.86.


Embracing model-based designs for dose-finding trials.

Love SB, Brown S, Weir CJ, Harbron C, Yap C, Gaschler-Markefski B, Matcham J, Caffrey L, McKevitt C, Clive S, Craddock C, Spicer J, Cornelius V.

Br J Cancer. 2017 Jul 25;117(3):332-339. doi: 10.1038/bjc.2017.186. Epub 2017 Jun 29. Review.


Improving Outcomes in High-Risk Myelodysplasia: Festina Lente.

Craddock C.

J Clin Oncol. 2017 Aug 20;35(24):2729-2731. doi: 10.1200/JCO.2017.73.0812. Epub 2017 May 26. No abstract available.


ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT.

Canaani J, Savani BN, Labopin M, Michallet M, Craddock C, Socié G, Volin L, Maertens JA, Crawley C, Blaise D, Ljungman PT, Cornelissen J, Russell N, Baron F, Gorin N, Esteve J, Ciceri F, Schmid C, Giebel S, Mohty M, Nagler A.

Am J Hematol. 2017 Aug;92(8):789-796. doi: 10.1002/ajh.24771. Epub 2017 Jun 9.


Allogeneic transplantation in primary refractory AML.

Ferguson P, Craddock C.

Bone Marrow Transplant. 2017 Jul;52(7):950-951. doi: 10.1038/bmt.2017.61. Epub 2017 Apr 24. No abstract available.


Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation.

Onida F, de Wreede LC, van Biezen A, Eikema DJ, Byrne JL, Iori AP, Schots R, Jungova A, Schetelig J, Finke J, Veelken H, Johansson JE, Craddock C, Stelljes M, Theobald M, Holler E, Schanz U, Schaap N, Bittenbring J, Olavarria E, Chalandon Y, Kröger N.

Br J Haematol. 2017 Jun;177(5):759-765. doi: 10.1111/bjh.14619. Epub 2017 Mar 28.


Fasting: starving cancer.

Cathcart P, Craddock C, Stebbing J.

Lancet Oncol. 2017 Apr;18(4):431. doi: 10.1016/S1470-2045(17)30196-1. No abstract available.


Impact of Alemtuzumab Scheduling on Graft-versus-Host Disease after Unrelated Donor Fludarabine and Melphalan Allografts.

Green K, Pearce K, Sellar RS, Jardine L, Nicolson PLR, Nagra S, Bigley V, Jackson G, Dickinson AM, Thomson K, Mackinnon S, Craddock C, Peggs KS, Collin M.

Biol Blood Marrow Transplant. 2017 May;23(5):805-812. doi: 10.1016/j.bbmt.2017.02.007. Epub 2017 Feb 14.


A comparison between allogeneic stem cell transplantation from unmanipulated haploidentical and unrelated donors in acute leukemia.

Piemontese S, Ciceri F, Labopin M, Arcese W, Kyrcz-Krzemien S, Santarone S, Huang H, Beelen D, Gorin NC, Craddock C, Gulbas Z, Bacigalupo A, Mohty M, Nagler A; Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

J Hematol Oncol. 2017 Jan 19;10(1):24. doi: 10.1186/s13045-017-0394-2.


Professor David Grimwade (1962-2016).

Russell NH, Freeman SD, Craddock C.

Bone Marrow Transplant. 2017 Feb;52(2):171-172. doi: 10.1038/bmt.2016.350. Epub 2017 Jan 16. No abstract available.


Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT.

Robin M, Porcher R, Zinke-Cerwenka W, van Biezen A, Volin L, Mufti G, Craddock C, Finke J, Richard C, Passweg J, Peniket A, Maertens J, Sucak G, Gedde-Dahl T, Vitek A, Nagler A, Blaise D, Beelen D, Maillard N, Schwerdtfeger R, de Witte T, Kroger N.

Bone Marrow Transplant. 2017 Feb;52(2):209-215. doi: 10.1038/bmt.2016.266. Epub 2016 Nov 7. Erratum in: Bone Marrow Transplant. 2017 Jul;52(7):1081.


An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group.

Haematologica. 2016 Nov;101(11):1351-1358. Epub 2016 Aug 18.


Cyclin-dependent kinase activity enhances phosphatidylcholine biosynthesis in Arabidopsis by repressing phosphatidic acid phosphohydrolase activity.

Craddock CP, Adams N, Kroon JT, Bryant FM, Hussey PJ, Kurup S, Eastmond PJ.

Plant J. 2017 Jan;89(1):3-14. doi: 10.1111/tpj.13321. Epub 2016 Dec 1.


Matched and mismatched unrelated donor compared to autologous stem cell transplantation for acute myeloid leukemia in first complete remission: a retrospective, propensity score-weighted analysis from the ALWP of the EBMT.

Saraceni F, Labopin M, Gorin NC, Blaise D, Tabrizi R, Volin L, Cornelissen J, Cahn JY, Chevallier P, Craddock C, Wu D, Huynh A, Arcese W, Mohty M, Nagler A; Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT).

J Hematol Oncol. 2016 Sep 2;9(1):79. doi: 10.1186/s13045-016-0314-x.


The impact of HLA-matching on reduced intensity conditioning regimen unrelated donor allogeneic stem cell transplantation for acute myeloid leukemia in patients above 50 years-a report from the EBMT acute leukemia working party.

Rubio MT, Savani BN, Labopin M, Polge E, Niederwieser D, Ganser A, Schwerdtfeger R, Ehninger G, Finke J, Renate A, Craddock C, Kröger N, Hallek M, Jindra P, Mohty M, Nagler A.

J Hematol Oncol. 2016 Aug 3;9(1):65. doi: 10.1186/s13045-016-0295-9.


Genetically distinct leukemic stem cells in human CD34- acute myeloid leukemia are arrested at a hemopoietic precursor-like stage.

Quek L, Otto GW, Garnett C, Lhermitte L, Karamitros D, Stoilova B, Lau IJ, Doondeea J, Usukhbayar B, Kennedy A, Metzner M, Goardon N, Ivey A, Allen C, Gale R, Davies B, Sternberg A, Killick S, Hunter H, Cahalin P, Price A, Carr A, Griffiths M, Virgo P, Mackinnon S, Grimwade D, Freeman S, Russell N, Craddock C, Mead A, Peniket A, Porcher C, Vyas P.

J Exp Med. 2016 Jul 25;213(8):1513-35. doi: 10.1084/jem.20151775. Epub 2016 Jul 4.

Supplemental Content

Loading ...
Support Center